Skip to main
INSP

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 18%
Buy 47%
Hold 35%
Sell 0%
Strong Sell 0%

Bulls say

Inspire Medical Systems Inc is exhibiting strong financial performance and growth potential, evidenced by a notable 56% increase in spending during 3Q25, which is anticipated to enhance awareness and drive procedures. The company's advertising expense rose by 34% year-over-year in 2023, reflecting a commitment to expanding its market presence, while management's guidance for 2025 indicates a significant increase in direct-to-consumer spending, alongside disciplined cost management measures. Additionally, Inspire is expected to increase its average selling price (ASP) beginning in 2026, which, combined with improved reimbursement prospects, is likely to boost both volume and revenue significantly.

Bears say

Inspire Medical Systems Inc. has experienced a deceleration in advertising expenditures, with a projected 2024 ad expense decrease of 5% year-over-year, signaling potential difficulties in marketing effectiveness. The launch of a critical new product, the Inspire 5, has encountered unforeseen challenges, prompting management to revise revenue and EPS expectations downwards, which negatively affects the stock valuation. Additionally, the company has made significant cuts to operational expenses, particularly in research and development, raising concerns about its ability to sustain growth and innovation in a competitive market.

INSP has been analyzed by 17 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 47% recommend Buy, 35% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Buy based on their latest research and market trends.

According to 17 analysts, INSP has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.59, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.59, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.